Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?

Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendarterectomy (PTE) surgery and all patients should be eva...

Full description

Bibliographic Details
Main Authors: Jenny Z. Yang, David S. Poch, Lawrence Ang, Ehtisham Mahmud, Nick H. Kim
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Pulmonary Circulation
Subjects:
Online Access:https://doi.org/10.1002/pul2.12312
_version_ 1827396464859414528
author Jenny Z. Yang
David S. Poch
Lawrence Ang
Ehtisham Mahmud
Nick H. Kim
author_facet Jenny Z. Yang
David S. Poch
Lawrence Ang
Ehtisham Mahmud
Nick H. Kim
author_sort Jenny Z. Yang
collection DOAJ
description Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendarterectomy (PTE) surgery and all patients should be evaluated for operability candidacy. Despite advancements in PTE technique allowing more segmental–subsegmental surgeries, up to a third of patients with CTEPH may still be considered inoperable. Over the past decade, there have been increasing treatment options for these inoperable CTEPH patients. Balloon pulmonary angioplasty (BPA) is a percutaneous‐based interventional treatment option for select CTEPH cases. Early BPA experiences were plagued by high complication rates, but further refinements in technique and equipment pioneered by Japan led to the worldwide spread and adoption of BPA. Multiple centers have shown that patients experience significant improvements in hemodynamics, quality of life, exercise capacity, and survival with BPA treatment. There remain many questions on best practices, but BPA has evolved into a pivotal cornerstone of CTEPH treatment.
first_indexed 2024-03-08T18:51:22Z
format Article
id doaj.art-c76824ada7b54539b46d418ae6621ce6
institution Directory Open Access Journal
issn 2045-8940
language English
last_indexed 2024-03-08T18:51:22Z
publishDate 2023-10-01
publisher Wiley
record_format Article
series Pulmonary Circulation
spelling doaj.art-c76824ada7b54539b46d418ae6621ce62023-12-28T19:02:35ZengWileyPulmonary Circulation2045-89402023-10-01134n/an/a10.1002/pul2.12312Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?Jenny Z. Yang0David S. Poch1Lawrence Ang2Ehtisham Mahmud3Nick H. Kim4Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Cardiovascular Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Cardiovascular Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine UC San Diego La Jolla California USAAbstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendarterectomy (PTE) surgery and all patients should be evaluated for operability candidacy. Despite advancements in PTE technique allowing more segmental–subsegmental surgeries, up to a third of patients with CTEPH may still be considered inoperable. Over the past decade, there have been increasing treatment options for these inoperable CTEPH patients. Balloon pulmonary angioplasty (BPA) is a percutaneous‐based interventional treatment option for select CTEPH cases. Early BPA experiences were plagued by high complication rates, but further refinements in technique and equipment pioneered by Japan led to the worldwide spread and adoption of BPA. Multiple centers have shown that patients experience significant improvements in hemodynamics, quality of life, exercise capacity, and survival with BPA treatment. There remain many questions on best practices, but BPA has evolved into a pivotal cornerstone of CTEPH treatment.https://doi.org/10.1002/pul2.12312balloon pulmonary angioplastyBPAchronic thromboembolic pulmonary diseaseCTEPHpulmonary vascular
spellingShingle Jenny Z. Yang
David S. Poch
Lawrence Ang
Ehtisham Mahmud
Nick H. Kim
Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
Pulmonary Circulation
balloon pulmonary angioplasty
BPA
chronic thromboembolic pulmonary disease
CTEPH
pulmonary vascular
title Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
title_full Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
title_fullStr Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
title_full_unstemmed Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
title_short Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
title_sort balloon pulmonary angioplasty in the current era of cteph treatment how did we get here
topic balloon pulmonary angioplasty
BPA
chronic thromboembolic pulmonary disease
CTEPH
pulmonary vascular
url https://doi.org/10.1002/pul2.12312
work_keys_str_mv AT jennyzyang balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere
AT davidspoch balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere
AT lawrenceang balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere
AT ehtishammahmud balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere
AT nickhkim balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere